The call gives researchers from various sectors the opportunity to participate in ambitious public-private partnerships for the development of future medicines.
IMI2 – Call 20 was launched on January 21, 2020 and is a call for standard two-stage proposals.
Why request?
– Obtain funds for research.
– Participate in a scientifically excellent patient-centered investigation
– Join unique consortia that involve the best teams in the industry, academia, SMEs, regulators and others.
– It means benefiting from the experience, databases and infrastructure of the consortium partners.
– Increase the visibility and status of your organization in Europe and worldwide and access to new markets.
Themes
– Early diagnosis, prediction of radiographic results and development of rational and personalized treatment strategies to improve long-term results in psoriatic arthritis.
– Innovations to accelerate the development and manufacture of vaccines.
– Academy merger in innovation and treatment for tuberculosis (UNITE4TB).
– Tumor plasticity.
– Proton versus photon therapy for esophageal cancer – trimodality strategy.
– Management of protein pharmacological products and stability problems.
More information on the topics: https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-20
Deadline for short proposals: April 21, 2020
CONTACT
Visit the IMI website: www.imi.europa.eu
For more information about the call you can contact projects1@idival.org
